804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models

• Jeffrey Schlom,
• Jacques Moisan,
• Claudia Palena,
• Kristen Fousek,
• Lucas A Horn,
• Andrew Bayliffe,
• Haiyan Qin,
• Shantel Angstadt,
• Madan Katragadda

Affiliations

Jeffrey Schlom

1National Cancer Institute, National Institutes of Health, Bethesda

Jacques Moisan

2Marengo Therapeutics, Cambridge, MA, USA

Claudia Palena

1National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Kristen Fousek

1National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Lucas A Horn

1National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Andrew Bayliffe

2Marengo Therapeutics, Cambridge, MA, USA

Haiyan Qin

1National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Shantel Angstadt

1National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Madan Katragadda

2Marengo Therapeutics, Cambridge, MA, USA